154 related articles for article (PubMed ID: 27729322)
21. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotype of neoplastic plasma cells in AL amyloidosis.
Deshmukh M; Elderfield K; Rahemtulla A; Naresh KN
J Clin Pathol; 2009 Aug; 62(8):724-30. PubMed ID: 19638544
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
[TBL] [Abstract][Full Text] [Related]
25. Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients.
Kern W; Bacher U; Haferlach C; Alpermann T; Schnittger S; Haferlach T
Cytometry B Clin Cytom; 2015; 88(3):154-64. PubMed ID: 25581461
[TBL] [Abstract][Full Text] [Related]
26. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
[TBL] [Abstract][Full Text] [Related]
27. Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.
Kriegsmann K; Dittrich T; Neuber B; Awwad MHS; Hegenbart U; Goldschmidt H; Hillengass J; Hose D; Seckinger A; Müller-Tidow C; Ho AD; Schönland S; Hundemer M
Cytometry B Clin Cytom; 2018 Sep; 94(5):611-620. PubMed ID: 29577600
[TBL] [Abstract][Full Text] [Related]
28. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
[TBL] [Abstract][Full Text] [Related]
29. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
30. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S
Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.
Muchtar E; Gertz MA; Kourelis TV; Sidana S; Go RS; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Lisa Hwa Y; Gonsalves W; Warsame R; Russell S; Lust JA; Lin Y; Zeldenrust S; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Leukemia; 2020 Apr; 34(4):1135-1143. PubMed ID: 31758090
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
[TBL] [Abstract][Full Text] [Related]
34. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma.
Ghosh T; Gonsalves WI; Jevremovic D; Dispenzieri A; Dingli D; Timm MM; Morice WG; Kapoor P; Kourelis TV; Lacy MQ; Hayman SR; Buadi FK; Leung N; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust SR; Warsame R; Hwa YL; Kyle RA; Gertz MA; Vincent Rajkumar S; Kumar SK
Am J Hematol; 2017 Sep; 92(9):E507-E512. PubMed ID: 28568244
[TBL] [Abstract][Full Text] [Related]
35. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients.
Perfetti V; Colli Vignarelli M; Anesi E; Garini P; Quaglini S; Ascari E; Merlini G
Haematologica; 1999 Mar; 84(3):218-21. PubMed ID: 10189385
[TBL] [Abstract][Full Text] [Related]
36. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
[TBL] [Abstract][Full Text] [Related]
37. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
Bochtler T; Hegenbart U; Kunz C; Benner A; Seckinger A; Dietrich S; Granzow M; Neben K; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
Amyloid; 2014 Mar; 21(1):9-17. PubMed ID: 24455967
[TBL] [Abstract][Full Text] [Related]
38. [Detection of abnormal plasma cells in bone marrow contributes to the diagnosis of primary systemic light chain amyloidosis-review].
Hu Y; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1251-5. PubMed ID: 23114159
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
40. Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
Kastritis E; Kostopoulos IV; Theodorakakou F; Fotiou D; Gavriatopoulou M; Migkou M; Tselegkidi MI; Roussou M; Papathoma A; Eleutherakis-Papaioakovou E; Dialoupi I; Kanellias N; Ntalianis A; Rousakis P; Trougakos IP; Tsitsilonis O; Gakiopoulou C; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):19-23. PubMed ID: 32783569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]